Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
919 articles by Ben Fidler
-
FDA extends review of Capricor cell therapy; Pain drug startup to go public
Aug. 24, 2026 -
Cancer vaccine win restores Wall Street’s faith in Moderna
Aug. 20, 2026 -
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
Aug. 6, 2026 -
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Aug. 5, 2026 -
Alnylam plunges as earnings deliver ‘one-two punch’
July 30, 2026 -
Capricor Duchenne cell therapy voted down by FDA panel
July 29, 2026 -
FDA scientists question Capricor data; Legend CEO steps down
July 27, 2026 -
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
July 27, 2026 -
Scribe secures $129M in a rare gene editing IPO
July 23, 2026 -
FDA panel endorses broader use of certain peptides
July 23, 2026 -
GSK lung cancer drug gets speedy approval following $10.6B deal
July 22, 2026 -
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
July 22, 2026 -
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
July 21, 2026 -
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
July 20, 2026 -
Merck wins first approval of a PCSK9 cholesterol pill
July 16, 2026 -
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
July 15, 2026 -
Agenus surges on study pivot; Apnimed lines up an IPO
July 13, 2026 -
AstraZeneca, Ionis drug fails big heart disease study in major setback
July 9, 2026 -
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
July 8, 2026 -
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
July 7, 2026 -
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
June 24, 2026 -
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
June 22, 2026 -
Pfizer CFO to step down; Denali sells a regulatory fast-pass
June 18, 2026 -
Roche stakes $700M on Nurix’s protein-degrading drug
June 8, 2026 -
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
June 8, 2026
